Presentations on Optimizing Management of ALL
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on Optimizing Management of ALL

From Adolescents to Adults

Not a member of My prIME? Join now for instant access.

Enhance your understanding of optimal treatment approaches for acute lymphoblastic leukemia (ALL) in adolescents/young adults (AYAs) and adults. These downloadable slides presented at our satellite symposium preceding the ASH Annual Meeting & Exposition cover a variety of therapeutic topics, including accurate diagnostic and minimal residual disease assessment techniques, optimal treatment strategies for patients with newly diagnosed and relapsed/refractory ALL, and new and emerging agents that address areas of continuing unmet clinical need.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 11, 2017

Expiration Date

Dec 11, 2018

Featured Expert

  • Nicola Gökbuget, MD, Goethe University, Frankfurt, Germany

Featured Topic

Diagnosis and risk assessment of ALL

Featured Expert

  • Nicola Gökbuget, MD, Goethe University, Frankfurt, Germany

Featured Topic

Induction therapy for adults with ALL

Featured Expert

  • Stephen E. Sallan, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Induction therapy for adolescents/young adults with ALL

Featured Expert

  • Ching-Hon Pui, MD, St Jude Children’s Research Hospital, Memphis, Tennessee, United States

Featured Topic

Minimal residual disease (MRD) and post-remission therapy

Featured Expert

  • Eunice Wang, MD, Roswell Park Cancer Institute, Buffalo, New York, United States

Featured Topic

Current strategies for relapsed/refractory ALL in AYAs and adults: Where we are now

Featured Expert

  • Susan O'Brien, MD, UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California, United States

Featured Topic

Emerging and novel therapies in ALL: What’s on the horizon?

Featured Expert

  • Susan O'Brien, MD, UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California, United States

Featured Topic

prIME Points™

The activity is specifically designed to meet the needs of medical oncologists, hematologists, and other healthcare professionals involved in the treatment of AYAs and adult patients with ALL.

After successful completion of this educational activity, participants should be able to:

  • Interpret patient- and disease-related factors to accurately diagnose and assess risk in AYAs and adults with ALL
  • Design optimal induction strategies for the initial treatment of adults with ALL
  • Design optimal induction strategies for the initial treatment of AYAs with ALL
  • Describe the role of assessing MRD in both the prognosis and treatment planning for AYAs and adults with ALL
  • Develop optimal strategies for relapsed/refractory ALL in the AYA and adult populations
  • Analyze the role of new and emerging therapies used to treat ALL in AYAs and adults

This educational activity is supported by grants from Amgen and Shire.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Gökbuget has disclosed that she has received research support, advisory board participation support, and speaker fees from Amgen, Jazz, Pfizer, and Shire. She also received research support and speaker fees from Novartis. She further disclosed advisory board participation support from Celgene, Erytech, Gilead, Janssen, Juno, and Kite Pharma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr O’Brien has disclosed that she has received consulting fees from Abbvie, Amgen, Aptose Biosciences Inc., Celgene, GlaxoSmithKline, Janssen Oncology, and Vaniam Group LLC. She also received research support from Acerta, Gilead, Pharmacylics, ProNAI, Regeneron, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pui has disclosed that he has received consulting fees from Adaptive Biotechnologies, Bristol-Myers Squibb, Erytech Pharma, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sallan has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wang has disclosed that she has received consulting fees from Pfizer, Spectrum, and Shire. She has performed contracted research for or received research support from Immunogen. She also received fees for participation in a speaker’s bureau from Incyte. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.